Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Alectinib Formulations
NCT02074553Phase 1Completed
- Sponsor
- Roche
- Start
- Feb 2014
- Primary completion
- Sep 2014
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of alectinib in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Roche. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Time Zero to Extrapolated Infinite Time, Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration and 1 more. Started Feb 2014; status: completed.
02
Drugs
alectinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02074553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02074553.